71822-97-4

Basic information

• Product Name: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one
• Synonyms: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one;3-amino-6-bromo-2-methyl-4-quinazolinone;3-amino-6-bromo-2-methyl-quinazolin-4-one;3-amino-6-bromo-2-methylquinazolin-4-one
• CAS NO: 71822-97-4
• Molecular Formula: C₉H₈BrN₃O
• Molecular Weight: 254.08332
• Mol File: 71822-97-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 196 °C(Solv: ethanol (64-17-5))
• Boiling Point: 412.5±47.0 °C(Predicted)
• Appearance: /
• Density: 1.79±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.21±0.70(Predicted)
• CAS DataBase Reference: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one(71822-97-4)
• EPA Substance Registry System: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one(71822-97-4)

Safety Data

• Hazardous Substances Data: 71822-97-4(Hazardous Substances Data)

Upstream product

• 118-92-3 anthranilic acid 
• 38985-79-4 5-bromo-N-acetylanthranilic acid 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 19165-25-4 2-methyl-6-bromo-4H-3,1-benzoxazine-4-one 

Downstream Products

• 1119264-27-5 C₁₇H₁₄BrN₃O₂ 
• 1119264-28-6 C₁₆H₁₂BrN₃O₂ 
• 71823-00-2 3-benzylideneamino-6-bromo-2-methyl-3H-quinazolin-4-one 

Relevant articles and documents

Synthesis and evaluation of anticancer, antiphospholipases, antiproteases, and antimetabolic syndrome activities of some 3H-quinazolin-4-one derivatives

Some new 3H-quinazolin-4-one derivatives were synthesised and screened for anticancer, antiphospholipases, antiproteases, and antimetabolic syndrome activities. Compound 15d was more potent in reducing the cell viabilities of HT-29 and SW620 cells lines to 38%, 36.7%, compared to 5-FU which demonstrated cell viabilities of 65.9 and 42.7% respectively. The IC50 values of 15d were ～20?μg/ml. Assessment of apoptotic activity revealed that 15d decreased the cell viability by down regulating Bcl2 and BclxL. Moreover, compounds, 8j, 8d/15a/15e, 5b, and 8f displayed lowered IC50 values than oleanolic acid against proinflammatory isoforms of hGV, hG-X, NmPLA2, and AmPLA2. In addition, 8d, 8h, 8j, 15a, 15b, 15e, and 15f showed better anti-α-amylase than quercetin, whereas 8g, 8h, and 8i showed higher anti-α-glucosidase activity than allopurinol. Thus, these compounds can be considered as potential antidiabetic agents. Finally, none of the compounds showed higher antiproteases or xanthine oxidase activities than the used reference drugs.

Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity

Abstract: A series of quinazoline clubbed 1,3,5-triazine derivatives (QCT) were synthesized and evaluated for their in vitro anticancer activity against HeLa (human cervical cancer), MCF-7 (human breast cancer cell), HL-60 (human promyelocytic leukemia cell), HepG2 (human Hepatocellular carcinoma cell), and one normal cell line HFF (human foreskin fibroblasts). In vitro assay result encouraged to further move towards in ovo anticancer evaluation using chick embryo. The series of QCT derivatives showed higher anticancer and antiangiogenic activity against HeLa and MCF-7 cell lines. In the series, synthetic molecule 8d, 8l, and 8m displayed significant activity. Further, these results substantiated by docking study on VGFR2. SAR study concluded that the potency of drugs depends on the nature of aliphatic substitution and the heterocyclic ring system. Graphical Abstract: [Figure not available: see fulltext.]

2-{2"-carbomyl-5"-[3′-amino-2′-methylmono/ dihalosubstituted quinazolin-4′(3'h)-onomethylene]- 1",3",4"-oxadiazol-2"-yl}-4,5-dihydroimidazolines as potential antihypertensive agents

Twelve new 2- {2"-carbomyl - 5" - [3′-amino-2′ - methylmono / dihalosubstituted quinazolin- 4′ (3'H) - onomethylene] - 1",3",4" - oxadiazol-2"-yl} -4, 5- dihydroimidazolines were prepared and evaluated for their cardiovascular activity. The most active compound of this series is 2-{2"- carbomyl-5"-[3′-amino-2′-methyl-6-bromoquinazolin-4′(3'H)-onomethylene]-",3",4"-oxadiazol-2"- yl}-4,5-dihydroimidazolines i.e. compound VIc.